Unlocking Relief: Exploring Non-Operative Solutions for Recalcitrant Greater Trochanteric Pain Syndrome; a Systematic Review and Meta-Analysis Publisher



Ghorbani M¹ ; Parsa A¹ ; Esmaeilian S² ; Moshtaghioon SA³ ; Mirzaei M¹ ; Rahmanipour E⁴ ; Daskareh M⁵ ; Mohammadi M⁶
Source: Journal of Orthopaedic Reports Published:2025

Abstract

Introduction: Greater trochanteric pain syndrome (GTPS) is a common condition with limited treatment options. Orthobiologics, particularly platelet-rich plasma (PRP), have emerged as potential alternatives to conventional therapies. This systematic review and meta-analysis aimed to assess the effectiveness and safety of orthobiologics for GTPS. Methods: We conducted a comprehensive search across multiple databases, identifying studies evaluating pain, function, and quality-of-life outcomes in GTPS. Inclusion criteria focused on randomized controlled trials (RCTs) and observational studies. Risk of bias was assessed using validated tools. Meta-analyses were performed where appropriate, with heterogeneity evaluated. Results: Twenty studies involving 811 participants were included, comprising 11 RCTs. PRP showed significant pain reductions (VAS 2.14–6 points) and functional improvements (HHS/WOMAC up to 40.3 points), outperforming corticosteroid injections in long-term outcomes. Quality-of-life metrics also improved, with PRP demonstrating reductions in depressive symptoms and gains in EQ-5D scores. Other orthobiologics like hyaluronic acid and bone marrow aspirate concentrate showed potential, though evidence was limited. PRP exhibited a favorable safety profile, with only minor adverse events reported. Conclusions: PRP offers significant and sustained benefits for GTPS, particularly in pain relief and functional improvement, with a favorable safety profile. However, further research is needed to standardize protocols and evaluate the efficacy of other orthobiologics. © 2025